Pediatrix Medical Group (NYSE:MD) Upgraded at StockNews.com

StockNews.com upgraded shares of Pediatrix Medical Group (NYSE:MD) from a hold rating to a buy rating in a report issued on Wednesday.

Other equities analysts have also issued research reports about the company. Jefferies Financial Group increased their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. UBS Group increased their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Finally, Mizuho boosted their price objective on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Stock Performance

Shares of NYSE MD opened at $15.22 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.31 billion, a P/E ratio of -4.97, a P/E/G ratio of 2.22 and a beta of 1.55. Pediatrix Medical Group has a 12 month low of $6.62 and a 12 month high of $16.41. The stock has a 50 day moving average of $12.38 and a 200-day moving average of $9.77.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same period in the prior year, the firm earned $0.29 earnings per share. The company’s revenue was up .9% on a year-over-year basis. As a group, equities research analysts predict that Pediatrix Medical Group will post 1.25 EPS for the current year.

Insider Activity

In related news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the transaction, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,208 shares of company stock worth $327,617. 2.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Aristeia Capital L.L.C. bought a new position in Pediatrix Medical Group in the 2nd quarter valued at approximately $687,000. Vanguard Group Inc. raised its stake in shares of Pediatrix Medical Group by 1.6% during the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after acquiring an additional 164,333 shares during the last quarter. Boston Partners raised its stake in shares of Pediatrix Medical Group by 34.0% during the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after acquiring an additional 453,254 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after purchasing an additional 7,241,400 shares during the period. Finally, ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group in the second quarter worth $1,721,000. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.